Stocks
Neurotrope Financial Statements (NTRP) |
||||||||||
| Neurotropesmart-lab.ru | % | 2020Q3 | 2022Q3 | 2022Q4 | 2023Q1 | 2023Q2 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 09.11.2020 | 31.12.2022 | 31.03.2023 | 30.06.2023 | 30.09.2023 | 30.09.2023 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.154 | 0.130 | 0.097 | 0.142 | 0.523 | |||
| Operating Income, bln rub | -2.58 | -1.94 | -1.78 | -1.30 | -0.900 | -5.93 | ||||
| EBITDA, bln rub | ? | -4.27 | -1.92 | -1.72 | -1.28 | -0.844 | -5.76 | |||
| Net profit, bln rub | ? | -4.27 | -1.95 | -1.75 | -1.31 | -0.872 | -5.88 | |||
| OCF, bln rub | ? | -3.25 | -1.83 | -1.31 | -1.11 | -0.172 | -4.41 | |||
| CAPEX, bln rub | ? | 0.000 | 0.129 | 0.048 | 0.057 | 0.040 | 0.275 | |||
| FCF, bln rub | ? | -3.25 | -1.95 | -1.36 | -1.16 | -0.212 | -4.69 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 2.58 | 2.06 | 1.85 | 1.36 | 0.866 | 6.14 | ||||
| Cost of production, bln rub | 0.000 | 0.037 | 0.064 | 0.036 | 0.176 | 0.313 | ||||
| R&D, bln rub | 0.410 | 0.211 | 0.127 | 0.105 | 0.000 | 0.443 | ||||
| Interest expenses, bln rub | 0.000 | 0.002 | 0.003 | 0.003 | 0.003 | 0.012 | ||||
| Assets, bln rub | 29.1 | 5.70 | 4.33 | 2.93 | 2.84 | 2.84 | ||||
| Net Assets, bln rub | ? | 27.8 | 5.07 | 3.56 | 2.39 | 1.97 | 1.97 | |||
| Debt, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Cash, bln rub | 27.0 | 2.85 | 1.49 | 0.368 | 0.556 | 0.556 | ||||
| Net debt, bln rub | -27.0 | -2.85 | -1.49 | -0.37 | -0.56 | -0.56 | ||||
| Ordinary share price, rub | 44.8 | 8.00 | 8.80 | 6.98 | 3.06 | 0.945 | ||||
| Number of ordinary shares, mln | 23.8 | 0.000 | 0.535 | 0.539 | 0.560 | 0.560 | ||||
| Market cap, bln rub | 1 065 | 0 | 5 | 4 | 2 | 1 | ||||
| EV, bln rub | ? | 1 038 | -3 | 3 | 3 | 1 | 0 | |||
| Book value, bln rub | 28 | 4 | 2 | 1 | 1 | 1 | ||||
| EPS, rub | ? | -0.18 | -3.28 | -2.43 | -1.56 | -10.5 | ||||
| FCF/share, rub | -0.14 | -2.54 | -2.16 | -0.38 | -8.37 | |||||
| BV/share, rub | 1.17 | 4.47 | 2.18 | 1.30 | 1.30 | |||||
| EBITDA margin, % | ? | -1 247% | -1 320% | -1 322% | -594.3% | -1 102% | ||||
| Net margin, % | ? | -1 266% | -1 346% | -1 348% | -613.9% | -1 124% | ||||
| FCF yield, % | ? | -0.79% | -180.1% | -205.5% | -273.4% | -885.4% | ||||
| ROE, % | ? | -44.4% | -230.3% | -306.6% | -387.9% | -297.7% | -297.7% | |||
| ROA, % | ? | -42.4% | -204.9% | -251.8% | -316.1% | -207.1% | -207.1% | |||
| P/E | ? | -86.2 | 0.00 | -0.43 | -0.41 | -0.29 | -0.09 | |||
| P/FCF | -126.5 | 0.00 | -0.56 | -0.49 | -0.37 | -0.11 | ||||
| P/S | ? | 0.00 | 16.6 | 9.87 | 3.28 | 1.01 | ||||
| P/BV | ? | 38.2 | 0.00 | 1.97 | 3.20 | 2.36 | 0.73 | |||
| EV/EBITDA | ? | -84.1 | 0.24 | -0.30 | -0.37 | -0.20 | 0.00 | |||
| Debt/EBITDA | 2.19 | 0.24 | 0.14 | 0.04 | 0.10 | 0.10 | ||||
| R&D/CAPEX, % | 163.3% | 265.7% | 183.3% | 0.61% | 161.3% | |||||
| CAPEX/Revenue, % | 83.9% | 36.6% | 59.2% | 28.4% | 52.5% | |||||
| Neurotrope shareholders | ||||||||||
